Indivior Share Discussion Threads

[gregmorg] 11/7/2018 11:06

Sublocade sales since launch had been a concern to certain people for reasons of which I have no knowledge. I understood they had no doubt the product was going to succeed big time medium term but shorter term aspects around the launch made them a tad uneasy. I heard the sentiment(although with no detail) but I dismissed it as just another story! Hopefully, whatever these issues they are now being addressed. As for the Suboxone situation. Well, a bit surprised but we await the outcome of the patent challenge. Agree Steeplejack that the picture painted re the Court injunction could have an importance. Meantime just hunkering down!

[steeplejack] 11/7/2018 10:16

"Sales of its new Sublocade treatment is progressing less rapidly than expected .."That's the key ,they've halved the revenue expectation for this year.Still expected to be a blockbuster but build up slower than anticipated.Meanwhile,Suboxone struggling due to a swift roll out of the generic by Dr Reddy before the Court injunction.Maybe the company is encouraged to make out the worst possible account of things in order to lend weight to its case for a defence of its patents.The worry is that when you have a president keen to tackle opioid addiction quickly and cheaply,generic companies like Dr Reddy feel emboldened to flout the rules,patents be damned.

[tsmith2] 11/7/2018 09:48

I'm scratching my head by the market reaction..

[grupo guitarlumber] 29/6/2018 11:38

Indivior PLC (INDV.LN) said Friday that the New Jersey district court extended the pharmaceutical company's temporary restraining order against Dr. Reddy's Laboratories Ltd. (RDY) for an additional 14 days.

The court reserved judgment on Indivior's motion and will consider the application during this period before ultimately issuing a ruling, the company said.

U.K.-listed Indivior had applied for a preliminary injunction against Dr. Reddy's Laboratories to ask for the cessation of its launch activities, and the first restraining order was issued on June 15.

Indivior had asked for a cessation of activities until there was an outcome of its recently filed litigation against the Indian company related to a U.S. patent, it said.



Write to Dimitrios Kontos at [e-mail]



(END) Dow Jones Newswires

June 29, 2018 03:27 ET (07:27 GMT)
Copyright (c) 2018 Dow Jones & Compan

[steeplejack] 29/6/2018 08:41

At the hearing, Judge McNulty reserved judgment on Indivior's motion, and has extended Indivior's temporary restraining order (TRO) issued on June 15, 2018 for an additional 14-days, during which time the Court will consider Indivior's application and ultimately issue a ruling on the PI.

[steeplejack] 28/6/2018 10:45

Point72asset management would appear to have closed their short.

[steeplejack] 27/6/2018 15:17

This PI motion will result in a hearing with the District Court where Indivior will seek to extend the cessation of launch activities by DRL pending the outcome of the recently filed litigation against DRL related to the '305 patent. A hearing on the preliminary injunction motion has been scheduled for June 28, 2018

[ljhrunner12] 22/6/2018 17:38

That's actually a recent reduction in reported short positions on 20th June, which more than offset the last reported increase back at the start of March.

[steeplejack] 22/6/2018 10:10

Short positions building recently Companies » INDIVIOR PLC Disclosed positions in INDIVIOR PLC (INDV)Notice: We no longer track disclosures after they drop below 0.5%. It is possible that the manager still holds a short position even if we are showing it as zero.Fund % short change Date changedPartner Fund Management, L.P. 0.92% 0.0% 15 Jun 2018Point72 Asset Management, L.P. 0.69% -0.21% 20 Jun 2018Wellington Management Company, LLP 0.84% 0.13% 1 Mar 2018Total 2.45%

[steeplejack] 18/6/2018 10:14

Post the Dr Reddy news,Jeffries reiterates buy with a 630p price target on June 15th.


Moodys hangs over the stock like the sword of Damoclese

[sarkasm] 18/6/2018 09:33

U.K. pharmaceutical company Indivior PLC (INDV.LN) said Monday that it has been successful in blocking--for the time being--the launch of a generic alternative to its Suboxone opioid disorder medication through the courts.

It said that the U.S. district court of New Jersey had granted it a restraining order compelling rival drugmaker Dr. Reddy's to temporarily cease activities related to the development and marketing of the product.

The order will stay until a hearing can take place on a preliminary injunction motion filed by Indivior. The company said it seeks to extend the ban on a launch of a generic Suboxone alternative.



Write to Carlo Martuscelli at [e-mail]



(END) Dow Jones Newswires

June 18, 2018 02:50 ET (06:50 GMT)

[sarkasm] 18/6/2018 08:51

Oliver Haill
WebFG News
18 Jun, 2018 08:36
Indivior hails court order blocking Dr Reddy's suboxone launch
indivior, invidior, suboxone
Indivior
374.20
08:33:37 18/06/18
3.80%
13.70
FTSE 250
20,963.75
08:33:47 18/06/18
-0.20%
-41.77
FTSE 350
4,257.08
08:33:47 18/06/18
-0.11%
-4.86
FTSE All-Share
4,205.68
08:33:47 18/06/18
-0.10%
-4.26

Indivior has won a temporary restraining order by a US court compelling rival drugmaker Dr Reddy's Labs to immediately stop any launch activities related to its generic version of Suboxone Film.

The US District Court for the District of New Jersey's restraining order will remain in place at least until a hearing on the preliminary injunction motion that Indivior filed on Friday when Dr Reddy’s won approval from the US drug regulator to produce a generic version of the sublingual film, which is used as a treatment for opioid addiction.

Dr Reddy's announced the approval from US Food & Drug Administration and said it would launch the buprenorphine and naloxone film.

This statement to launch was despite Indivior having recently filed litigation against Dr Reddy's and others related to the '305 patent.

On Monday, Indivior said it aimed to use the district court hearing, for which a preliminary injunction motion has been scheduled for 28 June, to seek to stop Dr Reddy's from launching its generic film pending the outcome of that litigation.

Chief executive Shaun Thaxter said: "We are pleased that the court has granted our request for a temporary restraining order. This order will stop Dr Reddy's launch activities before the court has had a chance to rule on the preliminary injunction motion. We will continue to pursue all legal avenues against Dr Reddy's to protect our Suboxone Film patent estate."

[dealy] 16/6/2018 14:08

makes sense Kazoom

[kazoom] 16/6/2018 12:58

I am new to Indivior so apologies if this doesn't make sense - please feel free to correct me ;-)

When I read "So Dr Reddy is really interested in testing punitive damages! I do wonder."

I wonder if Dr Reddy are actually engaged in some Trump style bargaining.

I note here (14-may) that INDV settled with PAR phara and that Par get the ability to sell the generic from Jan 2023

Maybe Reddy are angling for a similar settlement?

Also if Par don't have the rights until 2023 - why would we expect the courts to grant a later comer like Reddy earlier access to the market?

On that basis (and of course it could be nonsense) it seems to be that the outcome is likely to be much better than Friday's share price movement would suggest.

Any thoughts?

[steeplejack] 16/6/2018 08:39

https://uk.investing.com/news/stock-market-news/indivior-shares-dive-after-dr-reddys-gets-fda-approval-for-generic-1215680

[dealy] 16/6/2018 07:44

Well they have secured a temporary restraining order so hopefully big bounce on Monday

[steeplejack] 15/6/2018 22:52

Thanks for your comment Greg.Always appreciated.They'll be burning the midnight oil in the Standard Life HQ off Charlotte Square tonight!The company's response is solid enough and the market's response today frenetic.When we have days like this,I understand why the number of listed companies on the LSE has halved in the last 20 years.Whether the reaction be justifiable or not,the feral reaction of the market on the day (with all the implicit implications for the company)must be the biggest advert for a firm to go private imaginable.

[gregmorg] 15/6/2018 17:48

So Dr Reddy is really interested in testing punitive damages! I do wonder. The emphasis has to be on building up the more lucrative sublocade even faster whilst protecting as much of the film market share. Taking the longer term view and doing nothing- as always!.Also interesting announcement from Standard Life. Am overseas currently but from what I could see it bought quite a slug and had no notifiable interest previously. Someone else sold the stake of course.

[steeplejack] 15/6/2018 17:05

4 sept 2017?The shares are even now a good 30% higher than when you wrote that post.I think when Trump shows concern about opioid addiction,all will be done to get generic medication at a reasonable price to those who need it.Just how quickly Dr Reddy get their "at risk" product to the market remains to be seen.We all knew this was coming,it was a question of when.The good news is that there's a new injectable on the block .To be honest,I'm not sure whether I should be panicking or not.

[buywell3] 15/6/2018 16:37

buywell3 - 04 Sep 2017 - 07:47:52 - 304 of 394 RB. de-merger - INDV
There will be other legal actions coming to courts in the USA soon

The RISK here is that that Indivior could lose the next one

What would be the market reaction then ?

What is the date for the next court case ?


''In September, 35 U.S. states and the District of Columbia filed a lawsuit against Indivior alleging that it tried to keep generic versions of a drug off the market.

The lawsuit by the states alleged that Indivior took steps to get patients to switch to the oral strip version of Suboxone.''






Investing is about weighing up risks

Buying this stock today IMO is a punt
dyor

[steeplejack] 15/6/2018 11:19

Hargreaves and others are reasonably sanguine on this news and past price behaviour suggests that you'll be rewarded if you buy the falls.I'm surprised that they managed to get the stock down to 370 but the shares have been strong of late,recently topping 5 quid which prompted UBS to turn to a neutral stance.Understandable concerns over Suboxone generics have long haunted the shares but the future is all about Sublocade approved in the USA last November.Generics might ultimately track down Suboxone film but during the chase Sublocade should be up and running.

[jonmy7] 15/6/2018 10:40

I saw this as a buying opportunity as, with my very limited experience, the company looks strong to me. Brought at 391, it's since dropped further but I'm holding as I expect it to rise over the next 10 days.